Investment Q&A

Q: Hello Peter,
There have been many short sellers in the last few years in health care and now in Cannabis stocks. At this point, time will tell on Aphria, but for others like Valeant etc the short sellers were correct. I find it interesting that the brokerage firms, and analyst that covered these companies gave high marks and all of a sudden with a short report, they either revised their price targets or put out a release that the stock is under review rather than defend their own analysis. I am starting to question the analysis that is done by Canadian firms and their ratings. How is it that the short sellers are able to find things that the analysts covering these companies have not managed to even come across? Can you please comment as this is getting ridiculous when analysts and BNN Guests talk highly of companies and than we find out the shortfalls in these companies. Where is the accountability on these analysts and brokerage firms that put out good reports? Thanks very much

Q: Here is a Podcast of some people who went to all of Aphria's business locations and what they found out through their investigations about Aphria. This is somewhat disturbing and destructive information about Aphria.
Here is the link: https://seekingalpha.com/article/4225889-investigating-aphria-gabriel-grego-hindenburg-research

Q: Hello Peter,
With the cannabis stocks trading 50% below the legalization date, I would have thought any big companies that wanted to take an equity position in cannabis companies like Canntrust , Aphria, etc would have done it by now. Any thoughts on this? Also, I am starting to wonder if Knight is worth letting go now. This looks like a 30 year timeframe stock the way it is going... Appreciate the comments

Q: Good day gentlemen,
I am attempting to differentiate between the largest Canadian producers on a valuation basis...specifically EV/EBITDA. As 2018 and 2019 will be ramp up years for most of these companies, Can you provide this estimated figure for years 2019 and 2020 for these companies and any others you may have in this sector.

Q: Thank you for the special report on marijuana. I bought in Canopy growth prior to the liberals getting elected on the advice of a friend who assumed they would win and legalized weed...then sold at $15 thinking it was way too overvalued.

I am wanting to invest in a company again, would Aphria not be the safest place to put some money? They actually earn a profit as you detailed, why is it not being valued as high? Is it because they are not really players in the recreational market (yet)? They have the lowest cost and make money, seems like the best play? What am I missing?

Q: good morning all
What would be your recommendation for stocks in the medical marijuanna field
Thnks
CDJ

Q: What did you think of Aphria's earnings? Looks like they delivered eps of 9 cents a share when $0.00 was expected. Thompson Reuters has their current fiscal year (2019) estimates at 14 cents. Looks like a muted outlook considering what I thought was a pretty decent Q1.

Your thoughts?

Q: It is difficult to evaluate the cannabis industry at this early stage. I wonder if I can get your opinion on the Medical side of the industry. With a longer term outlook and possibly our Canadian companies supplying the world with high grade medical cannabis, can you talk a little about the Companies you like in order of perference?

Q: I have a investment in these three I have made money should I sell all or half off these before Mid Oct or hang on to one of these have you a favourite of these three
Thanks

Q: I feel the pot stocks have entered a bubble not unlike the tech bubble in 2000.

I think there could be a lot of money made on the short side here. Can you please suggest 2 or 3 stocks
In this area that you think have the highest chance of going to or near zero one this bubble bursts. Both US and Canadian equities.

Thanks

Sheldon

Q: Please give me your thoughts re Diageo interest in pot stocks. I have done very well on Canopy and currently over 400% increase, however I feel price is too high to buy more. I want to get some more exposure to pot market and am considering Aphria and Aurora. I note that Aurora has more than double the market cap of Aphria and I have heard that Aurora has through many stock only aquisitions is quite highly leveraged, and Aphria with the CEO having a Jameson background is more suited to medical side. Would you suggest buying a smaller position in both or select one? Thanks for your unbiased knowledge.
Cheers,Doug

Q: Would you pay $53 for Canopy Growth or would it be more prudent to allow the industry to get up and running before investing? What are your top 4 cannabis investments and why?
Thank you.

Q: I agree with your stated hypothesis that there will be further and probably significant consolidation in the Cannabis Industry.

Weed of course is leading the way and has made a significant move. Can you suggest 2 or 3 other cannabis stocks that you would think have the highest probability of being acquired and why you chose these.

Thank you

Sheldon

Q: If you were going to purchase one of the above cannabis companies today which would you choose and your thoughts on why?
Thks
Marcel

Q: Hello Peter,
What do you think about the joint venture between Hydropothecary and Molson's? Does this put Hydropothecary in the same category with Canopy (with Constellation equity) in terms of market perception? Aphria's results look fine, but why is the stock down? Is Brookfield Infrastructure a good buy given its takeover over of Enercare? Also, i noticed from BNN guests who are considered value investors that all of them had vary different views on Enercare from dont buy to hold to top pick. Can you shed some light as to why the views are so different given they all look at fundamentals? Lastly, what is happening with Grande West. It goes up and than back down again. Thanks.

Q: In light of CIBC's recently-released report that pot sales could reach $6.5B, which could top spirits' revenue, by 2020, what would your top three picks be and are they presently overvalued?
Thank you.

Q: I have a small position in Canopy. I would like to add one or two more marijuana stocks to my portfolio. Could you please make a few suggestions?

Many thanks, Peter

Q: Peter and team I have bought stock in this company I am down 30% should I dump it or try to average down , and what is your take on this company .
Jim.

Q: Good morning 5i
Many years ago I owned shares in Nvidia and Netflix and sold way to early, I think now is a similar entry point into the marijuana market which is already global if not legal.What would you think is the company with the most potential to expand into the States and perhaps Global, Aphria or Canopy Growth or do you have other companies that are on your radar that would be worth looking at for the longer term.
Best Regards,
Tom

Q: The Medical Marijauna space is still in it's infancy....what are you looking at to give it an investment profile to follow in 2018? thank you Van Campbell